Kabavir-L
Kabavir-L
Kabavir-L is a mixed combination of Abacavir Sulphate 300 and Lamivudine 300 mg. These mixed components are antiviral for human immunodeficiency virus from multiplying in body function and requirement. Both substitutes are nucleoside analogue reverse transcriptase inhibitors, a type of antiviral medicine similar to antiretrovirals. They are NRTIs. Intracellular kinases metabolize both agents sequentially to their respective 5’-triphosphates. They function as anti-HIV reverse transcriptase inhibitors. Both compositions significantly decrease the rapport for host-cell deoxyribonucleic acid polymerase.
Kabavir-L
Like purine guanine, abacavir is a synthetic carbaceous nucleoside analogue. Intracellular enzymes phosphorylate and deaminate it in three steps to produce the metabolite with activity triphosphate. It is an analogue of deoxyguanosine-5-triphosphate, which conflicts with endogenous dGTP and discourages its incorporation into HIV viral DNA. This stoppage of chain elongation inhibits viral proliferation.
Lamivudine, also called 3TC is a cytosine analogue. It undergoes several stages of phosphorylation, similar to ATP binding cassette, to produce the metabolite lamivudine triphosphate, which engages with endogenous cytosine. In the first step, deoxycytidine kinase catalyzes the chemical reaction of monophosphate. In the other step, cytidine phosphorylates the monophosphate to form the diphosphate.
The enzyme-nucleoside-diphosphato kinase converts diphosphates to triphosphates. Subsequently, the process phosphorylates 3TC; the primary mode of action inhibits HIV reverse transcription by terminating viral DNA chains. Note that the distinct phosphorylation pathways for 3TC and ABC exhibit variations.
Antiretroviral Medicine
Antiretroviral medicines, alternatively referred to as antiretroviral inhibitors, suppress replication by using a combination of medicines. This infection affects the immune system. Generally, human immunodeficiency source ailment by consuming immune, cells that the body functions need for an immune reaction. ART drugs can work by preventing several phases of the cycle. dGTP, which competes with the endogenous dGTP to preclude its incorporation into the HIV viral DNA.
Abacavir Sulphate-600mg and Lamivudine-300mg